Summary
Overview
Work History
Education
Skills
Accomplishments
Publications
Hobbies
Additional Information
Languages
Timeline
Generic

Angelos Oikonomopoulos

Millbrae,CA

Summary

Creative, highly motivated, and experienced scientist with more than 12 years of expertise in cardiovascular and autoimmune diseases, biomarker translational studies, and assay development. Published >25 peer-reviewed articles. Extensive experience in the application of novel technologies such as patient-derived iPSCs, biomarkers, genomic tools, gene-editing technologies, and HTS modalities towards target identification and validation. Excellent interpersonal communication, project management, and problem-solving skills. Strong ability to adapt to fast-paced dynamic matrix environments. Proven track record of collaborating with interdisciplinary teams and managing multiple projects. Passionate for translational research, the discovery of novel targets and therapeutic candidates in CVD. Seeking new opportunities to utilize skills and experience to benefit an organization and patients.

Overview

20
20
years of professional experience

Work History

Principal Scientist

Bristol Myers Squibb
04.2022 - Current
  • Scientific leader of 2 HTS programs targeting key pathogenic genes of genetic DCM
  • Developed internal high-scale iPSC-CM manufacturing capabilities to support HTS activities
  • Screened more than 150,000 compounds in iPSC-CMs to discover small molecule targeting key pathogenic gene of genetic DCM
  • Core member of molecular and cellular technologies group developing human iPSC disease models for research programs focused on genetic cardiomyopathies
  • Supported multiple internal teams with POC studies using several iPSC disease models of genetic cardiomyopathies
  • Managing and serving as scientific contact of several external collaborations with academic and industry partners
  • Managing team of 3 scientists (1 Associate Scientist, 1 Senior Associate Scientist, and 1 Scientist-PhD level).

Senior Scientist

Bristol Myers Squibb
12.2020 - 03.2022
  • Core member of multiple internal research programs
  • Drafted iPSC-CM report for NDA filling of Mavacamten (Camzyos)
  • Supported MOA studies and compound evaluation in multiple programs with HCM and DCM iPSC-CM disease models
  • Managed team of 2 (1 Associate Scientist and 1 Senior Associate Scientist).

Scientist II

MyoKardia Inc.
02.2020 - 11.2020
  • Supported translational team with biomarker analysis using disease models of human iPSC-CMs
  • Identified cytoprotective effects of Mavacamten using iPSC-CMs-Inventor in respective provisional patent
  • Established in-house sarcomere-based contractility assay (SarcTrack)
  • Managed team of 2 Associate Scientists (M.Sc. level)

Scientist I

MyoKardia Inc.
06.2018 - 01.2020
  • iPSC platform team leader-Set goals and experimental design in collaboration with project teams
  • Developed in-house assays for functional assessment of healthy and mutant human iPSC-CMs and supported pipeline by compound profiling and MOA studies using iPSC-CMs and supported pipeline by compound profiling and MOA studies using iPSC-CM
  • Communicate results to project teams, higher management, and Scientific Advisory Board
  • Contribute to multiple diligence teams for evaluation and identification of novel targets, modalities, and external collaborations
  • Managed 1 Associate Scientist (M.Sc. level) and mentored 1 summer intern (PhD Candidate).

Instructor

Stanford Cardiovascular Institute-Stanford University
04.2016 - 05.2018
  • Investigated inter-patient response to statins using control and patient-derived iPSC-CMs
  • Combined genomics and iPSC technologies to investigate the molecular signatures of clinically relevant concentrations of statins on human iPSC-CMs
  • Applied CRISPR/Cas9 technologies in human iPSCs to delineate the pathogenicity of a hERG VUS in cardiac channelopathies

Assistant Project Scientist

UCLA School of Medicine
08.2014 - 02.2016
  • Identified serum-derived non-coding RNAs (miRNAs) as IBD biomarkers
  • Investigated the role of epigenetic regulators (histone deacetylases) and non-coding RNAs in the molecular mechanisms of IBD and the immunosuppressive properties of mesenchymal stem cells
  • Evaluated xeno-free/serum-free media formulations for the expansion of mesenchymal stem cells
  • Scientific supervisor of the IBD Biobank of the Division of Digestive Diseases at UCLA
  • Established IBD Biobank from scratch (>5,000 specimens, 12 projects, 11 related publications)
  • Coordination of 2 associates, database maintenance, administrative duties, specimen collection, and QC
  • Developed collaborations with academia/industry (UCLA, Scripps Research Institute, Genentech, Takeda, Gilead).

Postdoctoral fellow

UCLA School of Medicine
08.2012 - 07.2014
  • Identified serum-derived non-coding RNAs (miRNAs) as IBD biomarkers
  • Investigated the role of epigenetic regulators (histone deacetylases) and non-coding RNAs in the molecular mechanisms of IBD and the immunosuppressive properties of mesenchymal stem cells
  • Evaluated xeno-free/serum-free media formulations for the expansion of mesenchymal stem cells
  • Established from scratch and supervised an IBD Biobank (>5,000 specimens, 12 projects, 11 related publications)
  • Developed collaborations with academia/industry (UCLA, Scripps Research Institute, Genentech, Takeda, Gilead).

Postdoctoral Fellow

Harvard Medical School
08.2011 - 05.2012
  • Studied the role of Wnt signaling and ABC transporters in adult mouse cardiac stem cell homeostasis, cardiac regeneration, and cardiomyocyte renewal using multiple in vitro and in vivo models (3 first author publications in Circulation research)
  • Examined the role of Fms-Related Tyrosine Kinase 3 (Flt3) in post-myocardial infarction remodeling

MSc Candidate

Boston University School of Medicine
09.2004 - 07.2006
  • Studied the contribution of bone marrow in cardiac regeneration following myocardial infarction.

Education

Ph.D. - Cardiovascular Biology

University of Crete, School of Medicine
Greece
04.2011

MSc - Molecular Mechanisms of Human Disease

University of Crete, School of Medicine
Greece
12.2006

BS - Biology

University of Crete, Biology Department
Greece
05.2004

Skills

  • Cellular biology: Human ESC, iPSCs, iPSC-CMs, various human and mouse cell lines, human PBMCs, T-cells, human BM and adipose MSC, iPSC-CM contractility and electrophysiology assays, cell proliferation/differentiation/apoptosis assays, development of stable cell lines, CFSE assays, MACS cell isolation, multicolor flow cytometry
  • Molecular biology: CRISPR/Cas9 genome editing, lentiviral vector design for gene expression manipulation, site-directed mutagenesis, transfection assays, DNA/RNA/protein isolation from tissues/cells/biofluids, qRT-PCR, Western blot, molecular cloning, transcriptomics, single and multiplex ELISA
  • In-vivo assays: Myocardial infarction/heart failure mouse models, bone marrow transplantation, In-vivo BrdU pulse/chase assays
  • Histological analysis: Processing of mouse cardiac tissue and human intestinal biopsies, confocal microscopy, immunofluorescence, immunohistochemistry
  • Bioinformatics/Software: Qlucore, Ingenuity (IPA), nSolver analysis software, GraphPad Prism 8, FlowJo, Endnote, Adobe Illustrator, Zeiss Zen
  • Instruments/Automation: xCELLigence RTCA (ACEA), Maestro Pro MEA system (AXION), Cytation multi-mode plate reader (BIOTEK), SI8000 Cell Motion Imaging System Sony, Nanostring nCounter platform, BD FACSAria, Sony FACS sorter, Zeiss confocal microscope, KEYENCE microscope, Image express high content imager

Accomplishments

  • Scientist Development Grant-AHA (2017-2020)
  • Award for 3rd best poster presentation at Harvard Medical School, Brigham and Women’s Hospital (2011)
  • Northeast affiliates Pre-doctoral Fellowship-AHA (2007-2009)

Publications

  • Wnt signaling exerts an antiproliferative effect on adult cardiac progenitor cells through IGFBP3, Oikonomopoulos A, Sereti KI, … Moon RT, Force T, Liao R, Circulation Research, Vol. 109, 1363, 2011
  • ATP-binding cassette G-subfamily transporter 2 regulates cell cycle progression and asymmetric division in mouse cardiac side population progenitor cells, Sereti KI, Oikonomopoulos A, … Qiu Y, Liao R, Circulation Research, Vol. 112, 27, 2013
  • Precision Medicine in Cardiac Channelopathy: Integrating Genome Editing and Induced Pluripotent Stem Cells to Decipher Variant of Unknown Significance, Garg P, Oikonomopoulos A, … Sanguinetti CM., Wu CJ, JAAC, Vol. 72, 62, 2008
  • Modeling Human Diseases with Induced Pluripotent Stem Cells: From 2D to 3D and beyond, Liu C, Oikonomopoulos A, Sayed N, Wu CJ, Development, Vol. 145, dev156166, 2018
  • Pluripotent stem cell-derived cardiomyocytes as a platform for cell therapy applications: Recent progress and obstacles for clinical translation, Oikonomopoulos A, Kitani T, Wu CJ, Molecular Therapy, Vol. 26, 1624, 2018
  • The effects of the left ventricular unloading on cardiomyocyte regeneration, Unno K, Oikonomopoulos A, Yanfei Y, … Sosnovik ED, Liao R, JMCC, Vol. 133, 174, 2019
  • Molecular Signatures of Beneficial Class Effects of Statins on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Tian L
  • Liu C, … Sayed N, Wu JC, Circulation, Vol. 141, 1208, 2020
  • Anti-TNF antibodies in Inflammatory Bowel Disease: do we finally know how it works?, Oikonomopoulos A, van Deen WK, Hommes WD, Curr Drug Targets, Vol. 14, 1421, 2013
  • Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media, Oikonomopoulos A#, van Deen KW, … Ziman A, Hommes WD, Nature Scientific Reports, Vol. 5, 16570, 2015, #Corresponding author
  • Identification of Circulating MicroRNA Signatures in Crohn’s Disease by using the Nanostring nCounter Technology, Oikonomopoulos A, Polytarchou C, Joshi S, Hommes DW, Iliopoulos D, Inflamm Bowel Dis, Vol. 22, 2063, 2016

Hobbies

Coaching AYSO youth soccer for the last 5 years all levels up to U10.

Started playing online chess during the pandemic and organized a zoom chess class for Spring Valley Elementary school in Millbrae. 

Additional Information

Employment Authorization: U.S. Permanent resident

Peer reviewer activity: Circulation, American Journal of Physiology-Heart and Circulatory Physiology (AJP-Heart), American Journal of Physiology - Gastrointestinal and Liver (AJP-GI), Cellular and Molecular Gastroenterology and Hepatology (CMGH)

Languages

Greek
Native or Bilingual
English
Full Professional

Timeline

Principal Scientist

Bristol Myers Squibb
04.2022 - Current

Senior Scientist

Bristol Myers Squibb
12.2020 - 03.2022

Scientist II

MyoKardia Inc.
02.2020 - 11.2020

Scientist I

MyoKardia Inc.
06.2018 - 01.2020

Instructor

Stanford Cardiovascular Institute-Stanford University
04.2016 - 05.2018

Assistant Project Scientist

UCLA School of Medicine
08.2014 - 02.2016

Postdoctoral fellow

UCLA School of Medicine
08.2012 - 07.2014

Postdoctoral Fellow

Harvard Medical School
08.2011 - 05.2012

MSc Candidate

Boston University School of Medicine
09.2004 - 07.2006

Ph.D. - Cardiovascular Biology

University of Crete, School of Medicine

MSc - Molecular Mechanisms of Human Disease

University of Crete, School of Medicine

BS - Biology

University of Crete, Biology Department
Angelos Oikonomopoulos